<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3011">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01689701</url>
  </required_header>
  <id_info>
    <org_study_id>PKU-EG-ECKL</org_study_id>
    <nct_id>NCT01689701</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators performed a double-blind parallel study in a group of Subjects Showing
      Erosive Gastritis who were given Hizikia Fusiformis Extract over a period of 4 weeks.
      Endoscopic observations were performed before and 4 weeks after the treatment, and the cure
      and improvement rates were investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Changes in number of erosions</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of erosions was measured in study visit 1(0 week) and visit 3(4 week).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in score of erosions</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Score of erosions was measured in study visit 1(0 week) and visit 3(4 week).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in subjects' symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>subjects' symptoms was measured in study visit 1(0 week) and visit 3(4 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gastrin</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Gastrin was measured in study visit 1(0 week) and visit 3(4 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pepsinogenⅠ</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PepsinogenⅠ was measured in study visit 1(0 week) and visit 3(4 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pepsinogenⅡ</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PepsinogenⅡ was measured in study visit 1(0 week) and visit 3(4 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pepsinogen Ⅰ/Ⅱ ratio</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pepsinogen Ⅰ/Ⅱ ratio was measured in study visit 1(0 week) and visit 3(4 week).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hs-CRP(High Sensitivity C-reactive Protein)</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hs-CRP(High Sensitivity C-reactive Protein) was measured in study visit 1(0 week) and visit 3(4 week).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Erosive Gastritis</condition>
  <arm_group>
    <arm_group_label>Hizikia Fusiformis extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hizikia Fusiformis extract</intervention_name>
    <description>Hizikia Fusiformis extract(1.3g/d)</description>
    <arm_group_label>Hizikia Fusiformis extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo(1.3g/d)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 19-70 years old

          -  Subjects Showing Erosive Gastritis (endoscopy)

          -  Able to give informed consent

        Exclusion Criteria:

          -  Diagnosed of gastrointestinal disease such as ulcer, cancer within 1 months

          -  Allergic or hypersensitive to any of the ingredients in the test products

          -  History of disease that could interfere with the test products or impede their
             absorption, such as gastrointestinal disease or gastrointestinal surgery

          -  Taken antibiotics and stomach medicines such as steroid, bismuth compound and proton
             pump inhibitor within 1 months

          -  Participation in any other clinical trials within past 2 months

          -  Laboratory test, medical or psychological conditions deemed by the investigators to
             interfere with successful participation in the study

          -  Pregnant or lactating women etc.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Wook Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 20, 2012</lastchanged_date>
  <firstreceived_date>September 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Erosive Gastritis</keyword>
  <keyword>Hizikia Fusiformis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastritis</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
